SEC Tracker
Get the app

Editas Medicine EDIT

Editas Medicine gets trial approval for EDIT-401

Form
8-K
Filed
Importance
Routine
  1. Phase 1/2 Strive trial approved in Australia
  2. EDIT-401 aims to reduce LDL-C by 90%
  3. Trial to start in 2026, data due Q1 2027
  4. Preclinical data shows 10-month LDL-C reduction

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Editas Medicine files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Merus MRUS
  2. Palvella Therapeutics PVLA public float $197M, Jun 30, 2025
  3. Esperion Therapeutics ESPR public float $198M, Jun 30, 2025
  4. Rezolute RZLT public float $204M, Dec 31, 2025
  5. Cardiff Oncology CRDF public float $205M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.